3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Metastatic Solid Tumors
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Interventions
Gemcitabine
18
Cisplatin
12
Oxaliplatin
7
pembrolizumab
6
Nivolumab
6
Capecitabine
4
trametinib
3
Fluorouracil
3
Bevacizumab
3
tremelimumab
2
lenvatinib
2
durvalumab
2
derazantinib
2
atezolizumab
2
Trastuzumab
2
Ramucirumab
2
Radiofrequency Ablation
2
Panitumumab
2
Leucovorin
2
Cryosurgery
2
zanidatamab
1
vandetanib
1
tucatinib
1
tocilizumab
1
telotristat ethyl
1
sargramostim
1
rucaparib
1
regorafenib
1
pertuzumab
1
milademetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Biliary Tract Neoplasms
×
sacituzumab govitecan
×
Clear all
No trials found.